test

Stephanie Halene MD, PhD

Assistant Professor of Medicine (Hematology)

Clinical Interests

Leukemia; myelodysplasia; myeloproliferative disorders; polycythemia; thrombocytosis; thrombocytopenia; sickle cell disease; thrombosis; coagulation


Board Certifications

2006
Hematology (Internal Medicine), Board Certified

Patient Care Locations

stephanie_halenefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Hematologic MalignanciesLongitudinal Assessment and Functional Outcomes in Patients with Hematologic Malignancies and Related Disorders
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Leukemia, not otherwise specified, Leukemia, other, and Myeloid and Monocytic LeukemiaA Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic LeukemiaA Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

More Clinical Trials...

Edit Profile